City State Bank Sells 250 Shares of Edwards Lifesciences Co. (NYSE:EW)

City State Bank reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 27.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 667 shares of the medical research company’s stock after selling 250 shares during the period. City State Bank’s holdings in Edwards Lifesciences were worth $49,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Purus Wealth Management LLC increased its holdings in Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after acquiring an additional 160 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management grew its stake in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after buying an additional 174 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock worth $1,417,000 after buying an additional 184 shares in the last quarter. Finally, Martin Capital Advisors LLP grew its stake in shares of Edwards Lifesciences by 0.7% in the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after buying an additional 186 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Trading Down 3.0 %

NYSE:EW opened at $71.20 on Tuesday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $41.99 billion, a P/E ratio of 10.27, a P/E/G ratio of 3.61 and a beta of 1.11. The firm has a 50-day simple moving average of $71.73 and a 200-day simple moving average of $71.77.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business posted $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup lifted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Barclays lifted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Jefferies Financial Group cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.40.

Insider Activity

In related news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,500 shares of company stock worth $2,160,800. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.